Evoke Pharma (NASDAQ:EVOK) Coverage Initiated at StockNews.com

Analysts at StockNews.com initiated coverage on shares of Evoke Pharma (NASDAQ:EVOK) in a research report issued to clients and investors on Saturday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.

Evoke Pharma Stock Up 9.0 %

Shares of Evoke Pharma stock opened at $4.71 on Friday. The company has a market cap of $7.02 million, a P/E ratio of -0.43 and a beta of 0.16. The firm’s 50 day moving average price is $5.00 and its 200-day moving average price is $5.33. Evoke Pharma has a 52-week low of $3.54 and a 52-week high of $15.13.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Evoke Pharma stock. Corsair Capital Management L.P. acquired a new position in Evoke Pharma, Inc. (NASDAQ:EVOK) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 11,667 shares of the specialty pharmaceutical company’s stock, valued at approximately $56,000. Corsair Capital Management L.P. owned about 1.42% of Evoke Pharma as of its most recent SEC filing.

About Evoke Pharma

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.